focus -WSS

focus

author：Wikipedia 2025-10-01 00:17:16 - browse：567

There are a lot of reasons why updated data on Pfizer’s Lorbrena, a treatment for non-small cell lung cancer, might not seem to be a big deal. The results are an update on the clinical trial that resulted in the Food and Drug Administration granting Lorbrena full approval in 2001, so in a sense they are not even that new. For Pfizer investors, Lorbrena isn’t that big a deal, either. The medicine, for patients whose lung tumors have particular genetic mutations, generated only $575 million last year — an amount that is up 57% from the year prior, but that still constitutes only 1% of the drug giant’s annual sales.

But there is one number that makes the Lorbrena data quite eye-catching: In the updated data, the daily pill decreased the risk that cancer would progress or that a patient would die by 81% over five years.

That’s a stunning number, especially when one considers that Lorbrena was not being compared to an inert placebo but to Xalkori, another Pfizer targeted cancer drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Google says AlphaFold 3 can map a vast universe of biomolecules

Wikipedia

hotspot

WSS

Software glitch causes Tandem insulin pump to shutdown, FDA warns

Readout LOUD podcast: What to know about H5N1 bird flu

First recipient of genetically engineered pig kidney has died

Complete sequence of Y chromosome published for first time

Australia’s approach to dialysis celebrates life

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Sports medicine is finally prioritizing gender equality

H5N1 communication has been strictly for the birds

Walensky prepares to leave CDC — and Congress — behind

AstraZeneca bets AAV gene therapy will still deliver the goods

Hollywood unions extend contract negotiations for actors

Researchers on aging grapple with how to calculate biological age

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

CDC wastewater surveillance dashboard to track bird flu hotspots

23andMe had bad news about my health. I wish a person had delivered it

As pharma fights Medicare drug negotiation, hospitals, docs silent

entertainment

Apellis safety probe of eye disease drug centers on injection needle

Shionogi licenses Pompe disease therapy from Maze Therapeutics

CDC wastewater surveillance dashboard to track bird flu hotspots

Making AI in medicine accessible to smaller, and rural hospitals

Brain worms: The science behind RFK Jr.'s parasitic infection

In science, is the line between industry and academia shifting?

Wikipedia

hotspot

focus

hotspot